In addition, lorlatinib after failure of first-line TKI in patients with advanced ROS1-positive NSCLC [NCT 04621188] (ALBATROS) phase two trial is expected for primary completion in March of 2025 [55]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.